Meet with… Astellas Venture Management
When:
Tue, March 10, 2015, 10:30am – 12:30pm
Where:
JLABS - 3210 Merryfield Row - San Diego, CA 92121
Description
When one door closes, another door opens. Investing opportunities don't stop after the JPMorgan conference, so join JLABS in welcoming Astellas Venture Management (AVM) /Innovation Management ("AIM") to San Diego on March 10th. AVM is the venture group within one of Japan's largest pharmaceutical companies, Astellas Pharma Inc. You may be familiar with some of AVM's successful, local portfolio companies including eFFECTOR Therapeutics and Fate Therapeutics. With hundreds of millions in an evergreen fund, AVM is looking to invest in more private companies in the early stage drug discovery and platform technology across several therapeutic areas, including:
- Immunology and Inflammation, Urology, Oncology, DM Complications, and Neuroscience
- Ophthalmology, Hearing Loss, Fibrosis, Autophagy and Regenerative Medicine.
Also, AVM has another mission by AIM to execute early stage innovative collaborations with Academia and biotech companies. Recent collaboration deals include Cancer Research UK (oncology target discovery), Harvard Medical School (ophthalmology target discovery), Dana-Farber Cancer Institute (oncology drug discovery) and Proteostasis (genetic disease drug discovery). AVM/AIM will provide equity and non-dilutive capitals to our portfolios and partners while actively looking for the new innovative opportunities.
